Introduction
Proton magnetic resonance spectroscopy (1H-MRS) in studies on the human brain requires relatively large voxels due to the low intensities of the metabolite signals. This poses a challenge for estimating metabolite concentrations in exclusively gray matter (GM) or white matter (WM) regions of interest (ROIs), since the voxels usually contain contributions from both GM and WM and, particularly in GM ROIs, cerebrospinal fluid (CSF). Several strategies exploiting spectroscopic imaging methods have been developed to estimate metabolite levels in pure GM or WM (1-7).
However, these methods are not suitable to single voxel studies using conventional volume selection. The application of the many variations of these sequences, including popular spectral editing techniques that often require especially large voxels (8) , by far dominates the use of 1H-MRS in studies on the brain.
Although mixed tissue contributions present a potential confound for interpreting single voxel 1H-MRS of the brain, determining the composition of the voxel by segmentation of a coregistered anatomical image allows correction for CSF, usually considered void of metabolites of interest at detectable levels, as well as the possibility of entering the tissue fraction of interest as a covariate in statistical analyses. Furthermore, if "absolute" concentrations are to be estimated, knowing the partial volume fractions allows the possibility of correcting for compartment-specific effects of relaxation on the observed signals (9) (10) (11) (12) (13) (14) . This is particularly important when using the water signal as a concentration standard since the water proton T1 and T2 relaxation times in GM, WM, and CSF differ markedly. Owing to the greater technical challenges of measuring the relaxation rates of metabolite signals (weak, overlapping, and often j-coupled), reports of their values have been inconsistent and, moreover, lacking for all metabolites of interest. However, when reported, the GM-WM differences have been small (reviewed by Di Costanzo et al. (15) ). Consequently, these differences have been ignored in most studies reporting concentration estimates of neurometabolites.
A formula for estimating molal concentrations (moles/Kg of tissue water) of neurometabolites that incorporates the effects of compartment-specific relaxation on the water signal has been described (13) . However, this formula does not account for tissue-specific effects of relaxation on metabolite signals but, instead, assumes that these rates are similar enough in GM and WM to incorporate them as a single factor. Here we extend the formula to include distinct metabolite relaxation terms and propose a similar equation for concentration estimates based on molarity (moles/L tissue). To our knowledge, an expression that correctly accounts for GM-and WM-specific metabolite relaxation in concentration estimates has not been previously reported.
The modified equation necessarily contains two unknown variables and, as such, is not solvable explicitly. Nonetheless, it is useful for examining the impact of differing GM and WM metabolite relaxation rates on the estimate of metabolite concentrations over a range of MRS parameters and assumptions.
Theory
Molality is concentration expressed in moles of solute per Kg of solvent. In brain tissue the solvent is water. The advantages of measuring molality in brain 1H-MRS experiments have been discussed in prior publications (13, 14) , and include insensitivity to temperature, barometric pressure, and the contribution of other solutes or non-soluble material to the solution. If the 1H-MRS signals are acquire under fully relaxed conditions (TE<<T2, TR>>T1), the molality of the metabolite protons is directly proportional to the ratio of the metabolite signal intensity SM to the water signal intensity SH2O, without assumptions about the water density in the tissue as is required with molarity. In the simplest case of a 1H-MRS voxel sampling only pure GM or pure WM molality is given by:
where [H2O]molal is the molality of pure water (55.49 moles/Kg water), #HM is the number of metabolite hydrogen atoms, 2 is the number of water protons, and both the water and metabolite fractions are assumed to be fully detected. If CSF is present in the voxel, the water signal is scaled by the tissue water mole fraction, fGM or fWM, or equivalently (1-fCSF), where fCSF is the CSF water mole fraction.
If the signals were not acquired under fully relaxed conditions, they must also be scaled by the appropriate T1-and T2-weighted relaxation factors. This is an important caveat, but one that could be avoided only with 1) knowledge of individual proton relaxation times which is, due to the difficulty of their measurement, lacking in the field, and
2) an accurate modeling of the total signal from each metabolite that takes into account any differing relaxation attenuation among its various spectral peaks. In the general case of partial volume contributions from GM, WM, and CSF, each with a compartment-specific water proton relaxation factor (RH2O_GM, RH2O_WM, RH2O_CSF) but assuming a common GM and WM metabolite relaxation factor (RM), the molality is given by (13) :
The fractions in Eq. [2] are not the volume fractions estimated by image segmentation, but the mole fractions of water. They can be related to the volume fractions by taking into account the relative water fraction in each segmentation fraction:
[4]
and [5] where fGM_vol, fWM_vol, and fCSF_vol are the GM, WM, and CSF volume fractions, respectively, estimated by segmentation, and the density factors (d) are the water densities associated with them.
Accounting for tissue-specific metabolite signal relaxation in the equation for molality is analogous to accounting for compartment-specific water signal relaxation (13 [6] and [7] where the fractions fGM, fWM, and fCSF are the mole fractions of water given by Eqs. [3] [4] [5] . The observed metabolite signal is equal to the sum of the mole fractions of the fully relaxed signal SM_R , with each fractional signal weighted by its compartment-specific relaxation factor: [8] Here R has been added to the subscript SM of Eq. [1] to emphasize that it is the total signal intensity (from all compartments) that would be observed under fully relaxed acquisition conditions. Solving for SM_R we obtain: [9] To account for the GM and WM metabolite signal fractions that are weighted by different relaxation factors, the term RM in Eq. [2] is substituted by the denominator of Eq. [9] . This term, which we label RM_GM_WM, can be expanded in terms of Eqs. [3] , [4] , [6] , and [7] . Further, the unknown GM and WM concentrations can be expressed as a single ratio to obtain:
Inserting this term into Eq. 2 we obtain:
[M]molal= SM_obs´(fGM´RH2O_GM + fWM´RH2O_WM + fCSF´RH2O_CSF) SH2O_obs´(1-fCSF)´RM_GM_WM´2 #HM´[ H2O]molal [11] Note that if the water and metabolite signals are acquired under fully relaxed conditions, Eq. [11] reduces to Eq. 
H2O]molar [12] In a voxel with a mixture of GM, WM, and CSF not sampled under fully relaxed conditions, the observed water signal SH2O_obs is the sum of the volume fractions of the fully relaxed signal SH2O_R from each compartment, with each fractional signal weighted by the relaxation factor and the water density of the compartment:
SH2O_obs= fGM_vol´dGM´SH2O_R´RH2O_GM + fWM_vol´SH2O_R´dWM´RH2O_WM + fCSF_vol´dCSF´SH2O_R´RH2O_CSF [13] As with the derivation of Eq.
[2], we solve for SH2O_R and substitute the resulting expression for SH2O in Eq. [12] . Assuming equal GM and WM metabolite signal relaxation times at this point, substituting SM_obs/RM for SM , and scaling SH2O by the tissue volume fraction to correct for the CSF inclusion yields:
where [H2O]molar is the molar concentration of pure water (55.49 moles/L).
To account for different metabolite signal relaxation rates in GM and WM, the term RM is replaced by RM_GM_WM to yield:
[17]
Methods
Equations [11] and [17] contain two unknown variables: the total tissue (GM+WM) metabolite concentration [M] and the ratio of GM to WM metabolite concentrations (inherent in RM_GM_WM). As such, they cannot be solved explicitly. However, approximations of the GM/WM metabolite ratio for various metabolites in healthy or in diseased tissue can be obtained from many published reports. In most of these studies, spectroscopic imaging data was used to estimate concentrations in several voxels with mixed GM, WM, and CSF content. Hypothetically pure GM and WM concentrations were estimated by regressing the concentrations against the fractional GM content of the voxel, normalized by the total tissue fraction, and extrapolating to fractions of 0 and 1 to estimate WM and GM concentrations, respectively (1) . To demonstrate the impact of differing GM and WM metabolite T1 and T2 times on concentration estimates in the present report, we examine real and simulated spectroscopic imaging data, allowing us to display the effect over a range tissue compositions typically encountered in brain 1H-MRS.
Simulated data were generated with programs written with Matlab (version R2014A, The
MathWorks Inc., www.matlab.com) by scaling hypothetical water and metabolite signals by the mole fractions and relaxation factors that would be associated with them in GM, WM, and CSF. The NAA measurements were obtained from a healthy human subject in a previously reported study (18) . Briefly, MRI anatomical and spectroscopic imaging data were acquired with a Siemens 3T Tim Trio scanner. 1H-MRS imaging was performed with a phase-encoded version of a double spin echo sequence, both with and without water presaturation (TE = 40 ms, TR = 1500 ms, slice thickness = 15mm, FOV = 220 x 220 mm, circular k-space sampling (radius = 12), total scan time = 582s). The MRS data were initially analyzed with LCModel (http://s-provencher.com) and then with Matlab programs that applied either Eqs. [11] or [17] . GM, WM, and CSF segmentaion maps were generated from a T1-weighted MPRAGE image using SPM5
(http://www.fil.ion.ucl.ac.uk/spm). The study was conducted with the approval of the Institutional Review Board of the University of New Mexico Health Sciences Center.
Results
To illustrate the effect of differing GM and WM metabolite relaxation times, we show only the case of molal concentrations, since the term RM_GM_WM is a scaling factor that will affect the molarity and molality expressions similarly. To this end, the GM-WM averaged T1 and T2 metabolite times in Eq. [11] were replaced by the tissue-specific times reported in reference 19 (T1GM_NAA = adjustment with a single tissue-averaged metabolite relaxation term would produce an estimate of pure GM NAA concentration that would be 7.8% lower than the estimate using tissue-specific relaxation times. In pure WM, this estimate would be 6.5% higher than the estimate using tissuespecific relaxation times. At TE = 0.006 s and TR = 6 s, ,on other hand, the maximum errors will be less than 0.5%.
Estimating absolute metabolite concentrations while accounting for compartment-specific GM and WM signal relaxation times requires an assumption about the GM/WM metabolite ratio in order to assign each fraction of the total metabolite signal to its distinct relaxation factor. The dotted line in Fig. 2 illustrates the error in the concentration estimate when there is an error in this ratio. For the representative case shown, the corrected data were simulated with TE=40 ms and TR=1.5 s. The dotted line shows the deviation from the correct concentrations when the GM/WM metabolite ratio is assumed to be 1.5 rather then the correct ratio of 1.2 (18/15). The errors in the concentrations will depend not only on the error in the ratio but on the tissue composition and assumed relaxation times. The error will be zero for voxels containing only WM or only GM and CSF and will be maximal at an intermediate mix of GM and WM. For the example shown the maximum error was less than 0.5%. *** Fig. 2 appears near here*** Illustrated in Fig. 2A is the application of Eqs. [11] and [17] to NAA measurements obtained from a healthy human subject with TE=40 ms and TR=1.5 s and corrected using the averaged T1
and T2 values for GM and WM used in the simulations. The regression plots of the corrected NAA concentrations versus normalized GM fraction demonstrate the basic differences between molarity and molality illustrated by the simulated data.
In Fig. 2B , the same raw data are plotted after correction with Eq. [11] assuming different metabolite signal T1 and T2 values in GM and WM (the same values used in the simulation) and a GM/WM NAA concentration ratio of 1.3. The latter factor was derived from the regression involving the data corrected with the same, averaged T1 and T2 times for both GM and WM (shown in Fig. 2A ).
Notable is the lower WM and higher GM extrapolated endpoints of the regression relative to the endpoints of the regression involving the molal data shown in Fig. 2A . The "100% WM" endpoint is 3.7% lower and the "100% GM" endpoint is 3.8% higher than these values when assuming single, averaged T1 and T2 values in both tissues, resulting in a higher GM/WM metabolite concentration ratio estimate of 1.4. This is similar to the results obtained in the simulated data analysis when the data were generated with TE=40 ms and TR=1.5 s and tissue-specific relaxation times were used rather than tissue-averaged times (bold line versus thin line for TE/TR = 0.04/1.5s in Fig. 1 ). The sum of the square residuals of the linear regression shown in Fig. 2A was within 0.1% of the sum of the square residuals of the linear regression shown in Fig. 2B . Hence, no improvement in the fit of the data to a straight line was observed when using tissue-specific relaxation factors to adjust the data in this case. To explore the possibility of converging toward a stable value for the metabolite ratio with an iterative application of Eq. [11] , the analysis was repeated assuming a GM/WM metabolite ratio of 1.4, but without a substantial change (<0.1%) in the results.
Discussion
The reliable estimation of neurometabolite concentrations by 1H-MRS is faced with numerous challenges (20) , not the least of which is the heterogeneity of the tissue within the voxel.
To simplify this problem, it is generally assumed that the sampled brain region is composed of only three compartments -GM, WM, and CSF -and, at times, a fourth compartment encompassing an MRI-detectable lesion. Each of these compartments is likely to have not only a different metabolite concentration and water density, but also different relaxation times associated with the signals. In a previous report, we presented Eq. [2] for adjusting molal concentration estimates for partial volume and water signal relaxation effects (13) . We also examined the impact of errors arising from estimates of the relative fractions of GM, WM, and CSF in the voxel (segmentation errors) as well as errors in the water signal relaxation times associated with those fractions. In the present report, we extend Eq. [2] , along with a similar equation for estimating molarity, to account for tissue-specific metabolite signal relaxation. To our knowledge, this is the first valid expression presented for accomplishing this. In view of alternative methods that have been proposed for performing this correction (16, 17) , it is worth emphasizing that scaling only the GM and WM volume or water fractions by the distinct metabolite relaxation factors is not equivalent to scaling the GM and WM metabolite signal fractions by these factors. In order to calculate the size of the latter signal fractions, the relative metabolite concentrations in GM and WM must be known or assumed.
Furthermore, any valid expression for correcting for metabolite signal relaxation differences must reduce to the simpler valid equations under simplifying conditions, such as when the observed signals are fully relaxed or when there is only a single tissue type in the voxel.
We analyzed the case of just one metabolite (NAA) at a field strength of 3T in this work, assuming relaxation times previously reported for that metabolite at 3T. These results, of course, can be extended to any metabolite under different sets of assumptions with respect to partial volume fractions, tissue concentrations, relaxation rates, and pulse parameters: the general trends in errors resulting from ignoring differences in tissue specific relaxation rates, or assuming inaccurate values, will be the same. Since the principle factor underlying these errors will be the difference in GM and WM metabolite relaxation times, knowledge of these times is essential to correcting for them accurately. Unfortunately, such information is lacking for most metabolites across the wide range of magnetic field strengths currently in use for brain studies, and few studies have attempted to measure the relaxation times of the various distinct proton signals that make up a metabolite spectrum. Adding to this uncertainty, metabolite relaxation times have been shown to vary with age, pathology, and brain region (21-24; and, given that metabolite T2 times appear to shorten with increasing field strength (25) (26) (27) (28) (29) while T1 times may lengthen (28, 29) , the sensitivity to TE and TR times is expected to increase at higher fields.
In the case of NAA at 3T, we estimate that when tissue-averaged relaxation times are used for GM and WM instead of tissue-specific relaxation times, errors of a few percent arise over the range of representative TE and TR values examined. These errors, of course, are maximal in pure GM and pure WM voxels and could be predicted based on the differing GM and WM relaxation rates alone. However, in voxels with mixed tissue composition, the full expression (Eq. 11) is needed to estimate the effects of tissue-specific relaxation. This entails that the relative metabolite concentrations in each compartment are assumed since, when dealing with real data, they are not known a priori. Reasonable assumptions about GM and WM metabolite concentrations might be obtained from prior estimates, for example, from multi-voxel studies in which the fractional signals were assumed to relax with common T1 and T2 times. In the present report, we adjusted NAA spectroscopic imaging data with different GM and WM NAA signal relaxation times using Eq. [11] and a GM/WM NAA ratio obtained from a prior analysis in which equivalent tissue-averaged GM and WM relaxation times were assumed. Repeating the tissue-specific analysis with the concentration ratio obtained in the prior analysis did not substantially alter the results (<0.1%). We note that this approach would not be feasible in single voxel studies; and, hence, assumptions about the GM/WM concentration ratio for any metabolite would be an important caveat in the interpretation of the results, particularly in studies on pathological tissue or differing regions of the brain. Though the errors in GM or WM metabolite concentration estimates are small in the simulated and real data analyses of this report, they nonetheless introduced a measurable analysis bias in the results.
To address the issue of tissue-specific water signal relaxation, a method was proposed to measure brain water signal relaxation and density differences on a voxel-by-voxel basis by acquiring in situ water relaxation and density maps along with 1H-MRS imaging data (31).
However, while reliably measuring the relaxation rates of the large water signal can be accomplished with straightforward imaging techniques, in situ GM and WM metabolite signal relaxation measurements are prohibitively time-consuming, technically challenging and, hence, impractical in a clinical setting. Given this impracticality, the most straightforward approach for improving the accuracy of absolute concentration estimates is simply to use acquisition parameters that minimize the impact of signal relaxation as much as possible, a remedy that has long been recommended to improve the accuracy of MRS concentration estimates. Minimizing T2 effects has become feasible with the advent of ultra-short-TE sequences (24, 32, 33) , while acquiring the water signal with a small pulse angle (24) reduces the impact of water signal T1 differences. Small pulse angles, unfortunately, are not practical for the acquisition of metabolite signals, and lengthening TR comes at a cost increasing the total acquisition time. For the example of the NAA signal and assumed relaxation times at 3T used in this report, we estimate the errors to be as large as 8% when TE= 144 ms and TR=1.5 s but less than 1% when tissue-averaged rather than tissue-specific relaxations are used for partial volume correction of data acquired with TE= 6 ms and TR=6 s.
In summary, the brain tissue milieu sampled by a typical MRS voxel is complex, conferring different MR properties on the detected signals depending on the cellular or extracellular compartment of origin. In order to interpret these signals in a practical manner, simplifying assumptions need to be made. In this report we present an extension of our earlier expression for correcting for partial volume effects in 1H-MRS data from the brain assuming three compartments:
GM, WM, and CSF. The fuller expression accounts for tissue-specific metabolite signal relaxation and requires assumptions not only with respect to the relaxation times, but with respect to the relative metabolite concentrations in GM and WM. With simulated data, we demonstrate the magnitude of the errors that arise when there are differences in GM and WM metabolite signal relaxation times that are not taken into account or when incorrect assumptions about the GM/WM concentration ratio are made. Given the substantial technical challenges of reliably measuring metabolite signal relaxation in situ, the simplest approach to reducing these errors is to acquire the data with pulse sequence parameters that minimize the effect of relaxation on the signal. 
